Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eylea, Regeneron and Amgen
Amgen gets early win in Regeneron lawsuit over Eylea biosimilar
Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a federal judge in West Virginia said on Monday.
Regeneron's stock drops as it loses bid to block Amgen's Eylea biosimilar
Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for blockbuster eye disease drug Eylea, the same judge has rejected the company’s attempt to block Amgen’s Eylea biosimilar.
Regeneron’s Eylea biosimilar fight heats up
Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock.
Regeneron falls after judge denies injunction blocking Amgen Eylea biosimilar (update)
Adds Wells Fargo analyst comment. Regeneron Pharmaceuticals (NASDAQ:REGN) quickly dropped 3.5% after a judge denied the company's motion for a preliminary injunction to block an Amgen (AMGN) biosimilar version of Regeneron's blockbuster Eylea drug.
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
Shares of
Regeneron
Pharmaceuticals, Inc. REGN were down 4.63% after an unfavorable ruling in its lawsuit against
Amgen
AMGN in the United States District Court for the Northern District of West ...
1d
on MSN
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales
AbbVie's (NYSE:ABBV) autoimmune disease biologic Humira (adalimumab) and Pfizer (NYSE:PFE)/BioNTech's (BNTX) COVID-19 shot ...
STAT
6d
Pharmalittle: We’re reading about a Regeneron biosimilar fight, a ‘positive surprise’ for Biogen lupus drug, and more
A U.S. judge ruled that Regeneron Pharmaceuticals cannot immediately block U.S. sales of a proposed copy of its blockbuster ...
3d
Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling
Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...
5d
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio. Click here to know what justifies a Buy rating ...
6d
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Regeneron sued Amgen in January, alleging that it was developing a biosimilar that violated key patent protections for Eylea.
FiercePharma
3d
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
Seeking Alpha
6d
Regeneron downgraded at Leerink after Amgen’s court win; Truist defends
Leerink Partners downgraded while Truist defended
Regeneron
(NASDAQ:REGN) after a judge denied the company’s motion for a preliminary injunction against
Amgen
(NASDAQ:AMGN) biosimilar for its ...
13h
Regeneron’s Growth Prospects Bolstered by Dupixent Approval and Promising Oncology Pipeline
Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback